Boots Vapour Chest Rub
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Boots Vapour Chest Rub
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Active Ingredients %w/w
Racemic Camphor 6%
Levomenthol natural or synthetic 1%
Eucalyptus Oil 1.5%
3. PHARMACEUTICAL FORM
Ointment
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
For head colds, stuffy nose, coughs and chest colds.
4.2. Posology and Method of Administration
Unless otherwise directed by the doctor:
For Adults and Children over 3 Months
Apply liberally to the chest and back particularly at bedtime. Use sparingly on infants and young children. Massage gently. For faster relief from a stuffy nose and tight chest, add one teaspoonful of Vapour Rub to half a pint of hot -not boiling - water and inhale the vapour.
Children under 3 Months
Not recommended for children under 3 months of age.
Elderly
There is no need for dosage reduction. For topical application and inhalation.
4.3. Contra-indications
Hypersensitivity to any of the ingredients.
4.4. Special Warnings and Precautions for Use
For external use only.
If symptoms do not go away talk to your pharmacist or doctor. Keep all medicines out of the reach of children.
4.5. Interactions with other Medicaments and other forms of Interaction
No clinically significant drug interactions known.
4.6. Pregnancy and Lactation
The safety of Vapour Rub during pregnancy and lactation has not been established but its use during these periods is not considered to constitute a hazard.
4.7. Effects on Ability to Drive and Use Machines
No adverse effects known.
4.8 Undesirable effects
Occasional hypersensitivity and irritant skin reactions.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
4.9 Overdose
Over dosage may result in skin irritation.
Misuse:
Swallowing of the ointment might cause gastrointestinal symptoms like vomiting and diarrhoea. Treatment is symptomatic.
Following oral ingestion, symptoms of overdosage may include colic, dizziness, delirium, muscle twitching, epileptiform convulsions and depression of the central nervous system. Breathing may be difficult. There may also be haematuria and albuminuria.
Acute poisoning was observed after significant accidental consumption, with nausea, vomiting, abdominal pain, and headache, vertigo, feeling hot / flushing, convulsions, respiratory depression and coma.
Patients with severe gastrointestinal or neurological symptoms of poisoning should be observed and treated symptomatically. Do not induce vomiting.
Convulsions may be controlled by the intravenous administration of diazepam 5-10 mg.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Eucalyptus Oil, Camphor and Levomenthol are volatile substances and are thought to produce an irritant effect on the respiratory tract, probably via a nasal/pulmonary arc.
5.2. Pharmacokinetic Properties
None stated.
5.3. Preclinical Safety Data
There are no preclinical data of relevance to the prescriber which are additional to that already included.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
White Soft Paraffin Thymol Turpentine Oil Pumilio Pine Oil BP’80
6.2. Incompatibilities
None stated.
6.3. Shelf Life
36 months.
6.4. Special Precautions for Storage
None.
6.5. Nature and Contents of Container
An amber glass jar with a tinplate cap with waxed aluminium faced pulpboard liner or a thermoset plastic cap with waxed aluminium faced pulpboard liner.
Pack size 45g.
Instruction for Use/Handling
6.6.
None stated.
7. MARKETING AUTHORISATION HOLDER
The Boots Company PLC 1 Thane Road West Nottingham NG2 3AA
8. MARKETING AUTHORISATION NUMBER(S)
PL 00014/5331R
9. DATE OF FIRST AUTHORISATION/RENEWAL OF
AUTHORISATION
Date of First Authorisation: 29 August 1984
Date of Last Renewal: 23 May 1996
10 DATE OF REVISION OF THE TEXT
24th March 2015